Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-10-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, and cash flow statements for the third quarter of 2023. The document explicitly states it is an unaudited quarterly report and includes comprehensive financial figures and analysis for the period. It also includes shareholder information and management changes but the primary content is the quarterly financial report. The length of the document (over 13,000 characters) and the presence of detailed financial statements confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2023
2023-10-27 Chinese
关于海创药业股份有限公司自愿披露关于氘恩扎鲁胺原料药供应商自行撤回原料药登记备案关联制剂申请被动撤回事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure by CITIC Securities regarding a voluntary disclosure by Haichuang Pharmaceutical about the withdrawal of a drug registration application by a raw material supplier, leading to a passive withdrawal of the related drug application. It includes regulatory references, risk disclosures, impact on company operations, and a verification opinion by the sponsor. The document is about a specific regulatory event and investigation related to drug registration and supply chain issues, not a financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a simple announcement of a report. It is a regulatory disclosure related to compliance and operational risk, fitting best under Regulatory Filings (RNS) as it does not fit other categories like Legal Proceedings or Capital Updates. The document length is short (2064 characters), but it contains substantive content rather than just announcing a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2023-10-23 Chinese
自愿披露关于氘恩扎鲁胺原料药供应商自行撤回原料药登记备案关联制剂申请被动撤回的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company HaiChuang Pharmaceutical regarding the withdrawal of a raw material drug registration by their supplier, which affects their drug application process. It contains no financial statements, no management discussion of financial results, no earnings data, and no regulatory certifications. The document is an operational update about a regulatory and supply chain issue impacting the company's drug approval timeline. It is not a financial report, audit, or earnings release. It is also not a meeting material, voting result, or capital change announcement. The document is a regulatory announcement informing investors about a material event affecting the company’s product development and regulatory filings. Given the nature and length (1817 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-20 Chinese
首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, the dates, shareholder commitments, and includes verification from intermediaries. The document is not a financial report, earnings release, or management discussion, but rather a formal notification about share circulation status. This fits the category of Share Issue/Capital Change announcements, as it concerns the unlocking and listing of restricted shares post-IPO.
2023-09-20 Chinese
中信证券股份有限公司关于海创药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Haichuang Pharmaceutical Co., Ltd. It references regulatory approvals, shareholding details, lock-up commitments, and compliance with relevant laws and stock exchange rules. The document is not an announcement of a report publication but a substantive verification opinion related to share circulation post-IPO. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not about management changes, voting results, or legal proceedings. The document is a formal verification opinion by the sponsor on share circulation compliance, which fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories.
2023-09-20 Chinese
第二届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the second supervisory board of the company. It details the meeting attendance, the election of the supervisory board chairman, and voting results. It does not contain financial data, audit results, or detailed management discussion. It is an announcement related to board/management changes, specifically the election of a supervisory board chairman. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full report or financial disclosure.
2023-09-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.